Advertisement
Research Article

Oral Ondansetron Administration in Emergency Departments to Children with Gastroenteritis: An Economic Analysis

  • Stephen B. Freedman mail,

    stephen.freedman@sickkids.ca

    Affiliations: Division of Pediatric Emergency Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada, The University of Toronto, Toronto, Ontario, Canada

    X
  • Michael J. Steiner,

    Affiliation: Department of Pediatrics, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America

    X
  • Kevin J. Chan

    Affiliations: Division of Pediatric Emergency Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada, The University of Toronto, Toronto, Ontario, Canada, Munk Centre for Global Studies, Toronto, Ontario, Canada

    X
  • Published: October 12, 2010
  • DOI: 10.1371/journal.pmed.1000350

About the Authors

Stephen B. Freedman, Kevin J. Chan
Division of Pediatric Emergency Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
Stephen B. Freedman
Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada
Stephen B. Freedman, Kevin J. Chan
The University of Toronto, Toronto, Ontario, Canada
Michael J. Steiner
Department of Pediatrics, The University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
Kevin J. Chan
Munk Centre for Global Studies, Toronto, Ontario, Canada

Corresponding Author

Email: stephen.freedman@sickkids.ca

Competing Interests

All authors declare that SF, MS, KC have no relationships with GlaxoSmithKline that might have an interest in the submitted work in the previous 3 years; their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and SF, MS, KC have no nonfinancial interests that may be relevant to the submitted work. SBF does acknowledge that he received research support from GlaxoSmithKline in 2003 but has not had any relationship with them since. He currently receives research support from Institut Rosell Lallemand. KJC previously received research support from GlaxoSmithKline (2000–2004) but has not had any relationship with them since.

Author Contributions

ICMJE criteria for authorship read and met: SBF MJS KJC. Agree with the manuscript's results and conclusions: SBF MJS KJC. Designed the experiments/the study: SBF MJS KJC. Analyzed the data: SBF KJC. Collected data/did experiments for the study: SBF MJS. Wrote the first draft of the paper: SBF. Contributed to the writing of the paper: SBF MJS KJC.